TYK MEDICINES-B (02410) gained over 4% in afternoon trading. As of the time of writing, the stock was up 3.87%, trading at HK$14.21, with a turnover of HK$59.4029 million. The movement follows the company's announcement that its self-developed Class 1 new drug, Mesylate Aidotinib Tablets (TY-9591 Tablets), has been proposed by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for inclusion in the priority review list. The intended indication is for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations, accompanied by central nervous system (CNS) metastases.
- Like
- Comment
- Favorite
Hong Kong Market Movement | TYK MEDICINES-B (02410) Rises Over 4% in Afternoon Session; Mesylate Aidotinib Tablets (TY-9591 Tablets) Proposed for Priority Review
Stock News01-09
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Like
Report
Login to post
No comments yet